| IMMUNIC INC. NEW O.N. |
| USA |
| Gesundheit |
| US4525EP2001 / A428WY |
| 10V (Frankfurt) / IMUX (NASDAQ) |
| FRA:10V, ETR:10V, 10V:GR, NASDAQ:IMUX |
| - |
| https://imux.com/ |
|
Immunic, Inc. is a clinical-stage biopharmaceutical company focused on developing selective oral therapies for immune-mediated and neurologic diseases. Headquartered in New York, United States, the company concentrates on small-molecule drugs designe..
>Volltext.. |
| 168.52 Mio. EUR |
| 7.89 Mio. EUR |
| - |
| -94.72 Mio. EUR |
| -90.23 Mio. EUR |
| -5.22 EUR |
| 0.36 Mio. EUR |
| 161.46 Mio. EUR |
| -70.36 Mio. EUR |
| 4.86 |
| - |
| -1.3% |
| - |
| - |
| - |
| - |
| IMMUNIC |
| 11.08.26 |
|